S&P 500   3,167.35 (-1.81%)
DOW   27,434.75 (-1.88%)
QQQ   218.08 (-1.50%)
AAPL   294.10 (-1.37%)
FB   200.05 (-0.33%)
MSFT   170.76 (-0.08%)
GOOGL   1,407.11 (-0.90%)
AMZN   1,981.85 (-1.37%)
CGC   19.66 (-3.15%)
BABA   206.44 (+0.14%)
GE   11.38 (-4.05%)
TSLA   802.03 (-3.81%)
AMD   48.03 (-2.22%)
T   37.81 (-0.63%)
ACB   1.50 (-3.23%)
F   7.35 (-2.91%)
PRI   124.57 (-1.89%)
BAC   31.60 (-3.45%)
DIS   129.68 (-2.50%)
GILD   69.75 (-4.33%)
S&P 500   3,167.35 (-1.81%)
DOW   27,434.75 (-1.88%)
QQQ   218.08 (-1.50%)
AAPL   294.10 (-1.37%)
FB   200.05 (-0.33%)
MSFT   170.76 (-0.08%)
GOOGL   1,407.11 (-0.90%)
AMZN   1,981.85 (-1.37%)
CGC   19.66 (-3.15%)
BABA   206.44 (+0.14%)
GE   11.38 (-4.05%)
TSLA   802.03 (-3.81%)
AMD   48.03 (-2.22%)
T   37.81 (-0.63%)
ACB   1.50 (-3.23%)
F   7.35 (-2.91%)
PRI   124.57 (-1.89%)
BAC   31.60 (-3.45%)
DIS   129.68 (-2.50%)
GILD   69.75 (-4.33%)
S&P 500   3,167.35 (-1.81%)
DOW   27,434.75 (-1.88%)
QQQ   218.08 (-1.50%)
AAPL   294.10 (-1.37%)
FB   200.05 (-0.33%)
MSFT   170.76 (-0.08%)
GOOGL   1,407.11 (-0.90%)
AMZN   1,981.85 (-1.37%)
CGC   19.66 (-3.15%)
BABA   206.44 (+0.14%)
GE   11.38 (-4.05%)
TSLA   802.03 (-3.81%)
AMD   48.03 (-2.22%)
T   37.81 (-0.63%)
ACB   1.50 (-3.23%)
F   7.35 (-2.91%)
PRI   124.57 (-1.89%)
BAC   31.60 (-3.45%)
DIS   129.68 (-2.50%)
GILD   69.75 (-4.33%)
S&P 500   3,167.35 (-1.81%)
DOW   27,434.75 (-1.88%)
QQQ   218.08 (-1.50%)
AAPL   294.10 (-1.37%)
FB   200.05 (-0.33%)
MSFT   170.76 (-0.08%)
GOOGL   1,407.11 (-0.90%)
AMZN   1,981.85 (-1.37%)
CGC   19.66 (-3.15%)
BABA   206.44 (+0.14%)
GE   11.38 (-4.05%)
TSLA   802.03 (-3.81%)
AMD   48.03 (-2.22%)
T   37.81 (-0.63%)
ACB   1.50 (-3.23%)
F   7.35 (-2.91%)
PRI   124.57 (-1.89%)
BAC   31.60 (-3.45%)
DIS   129.68 (-2.50%)
GILD   69.75 (-4.33%)
Log in

NYSE:ZTS - Zoetis Stock Price, Forecast & News

$136.02
-2.37 (-1.71 %)
(As of 02/25/2020 01:22 PM ET)
Today's Range
$135.31
Now: $136.02
$138.79
50-Day Range
$133.10
MA: $138.99
$144.94
52-Week Range
$91.21
Now: $136.02
$146.26
Volume60,070 shs
Average Volume1.98 million shs
Market Capitalization$64.60 billion
P/E Ratio43.60
Dividend Yield0.56%
Beta0.81
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP98978V10
Phone973-822-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.26 billion
Cash Flow$4.35 per share
Book Value$5.69 per share

Profitability

Net Income$1.50 billion

Miscellaneous

Employees10,600
Market Cap$64.60 billion
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive ZTS News and Ratings via Email

Sign-up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter.


Zoetis (NYSE:ZTS) Frequently Asked Questions

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis declared a quarterly dividend on Tuesday, February 11th. Shareholders of record on Friday, April 17th will be paid a dividend of $0.20 per share on Monday, June 1st. This represents a $0.80 dividend on an annualized basis and a yield of 0.59%. The ex-dividend date of this dividend is Thursday, April 16th. View Zoetis' Dividend History.

How will Zoetis' stock buyback program work?

Zoetis declared that its board has authorized a stock repurchase plan on Wednesday, December 12th 2018, which permits the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase up to 4.7% of its shares through open market purchases. Shares buyback plans are often an indication that the company's board believes its shares are undervalued.

How were Zoetis' earnings last quarter?

Zoetis Inc (NYSE:ZTS) issued its quarterly earnings results on Thursday, February, 13th. The company reported $0.92 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.88 by $0.04. The business had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.64 billion. Zoetis had a return on equity of 69.41% and a net margin of 23.96%. The business's quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.79 EPS. View Zoetis' Earnings History.

When is Zoetis' next earnings date?

Zoetis is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Zoetis.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis issued an update on its FY20 earnings guidance on Thursday, February, 13th. The company provided EPS guidance of $3.90-4.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.01. The company issued revenue guidance of $6.65-6.80 billion, compared to the consensus revenue estimate of $6.69 billion.

What price target have analysts set for ZTS?

16 brokers have issued 12 month price objectives for Zoetis' shares. Their forecasts range from $105.00 to $160.00. On average, they expect Zoetis' share price to reach $135.80 in the next twelve months. This suggests that the stock has a possible downside of 0.1%. View Analyst Price Targets for Zoetis.

What is the consensus analysts' recommendation for Zoetis?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 7 hold ratings, 7 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zoetis.

Has Zoetis been receiving favorable news coverage?

Media headlines about ZTS stock have trended negative on Tuesday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Zoetis earned a news impact score of -2.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Zoetis.

Are investors shorting Zoetis?

Zoetis saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 5,190,000 shares, a decrease of 12.6% from the January 15th total of 5,940,000 shares. Based on an average daily volume of 2,140,000 shares, the short-interest ratio is currently 2.4 days. Currently, 1.1% of the shares of the stock are short sold. View Zoetis' Current Options Chain.

Who are some of Zoetis' key competitors?

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).

Who are Zoetis' key executives?

Zoetis' management team includes the folowing people:
  • Mr. Juan Ramón Alaix, CEO & Director (Age 68)
  • Mr. Glenn C. David, Exec. VP & CFO (Age 47)
  • Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 58)
  • Mr. Clinton A. Lewis Jr., EVP and Grp Pres of Intl. Ops., Comm. Devp., Glbl Genetics, Aquatic Health & Human Medical Digs (Age 52)
  • Ms. Kristin C. Peck, Exec. VP and Group Pres of U.S. Operations, Bus. Devel. & Strategy (Age 48)

Who are Zoetis' major shareholders?

Zoetis' stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (4.17%), Alliancebernstein L.P. (2.94%), FMR LLC (2.45%), Polen Capital Management LLC (2.27%), Capital World Investors (2.02%) and Massachusetts Financial Services Co. MA (1.67%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Institutional Ownership Trends for Zoetis.

Which institutional investors are selling Zoetis stock?

ZTS stock was sold by a variety of institutional investors in the last quarter, including Sonora Investment Management LLC, Capital World Investors, Janus Henderson Group PLC, FMR LLC, 1832 Asset Management L.P., Cantillon Capital Management LLC, Artemis Investment Management LLP and Renaissance Technologies LLC. Company insiders that have sold Zoetis company stock in the last year include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Insider Buying and Selling for Zoetis.

Which institutional investors are buying Zoetis stock?

ZTS stock was acquired by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Sands Capital Management LLC, Geode Capital Management LLC, Goldman Sachs Group Inc., Milestone Resources Group Ltd, Marshall Wace LLP, Credit Suisse AG and UBS Group AG. View Insider Buying and Selling for Zoetis.

How do I buy shares of Zoetis?

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $135.88.

How big of a company is Zoetis?

Zoetis has a market capitalization of $64.53 billion and generates $6.26 billion in revenue each year. The company earns $1.50 billion in net income (profit) each year or $3.64 on an earnings per share basis. Zoetis employs 10,600 workers across the globe.View Additional Information About Zoetis.

What is Zoetis' official website?

The official website for Zoetis is http://www.zoetis.com/.

How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]


MarketBeat Community Rating for Zoetis (NYSE ZTS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  789 (Vote Outperform)
Underperform Votes:  459 (Vote Underperform)
Total Votes:  1,248
MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe ZTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Featured Article: S&P 500 Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel